Chai Discovery's Big Leap: Leading AI-Driven Drug Development with Eli Lilly Partnership
Chai Discovery, an AI-driven drug development company, has soared to prominence with its innovative Chai-2 platform, revolutionizing the process of biologics discovery. From its roots at OpenAI, Chai has now partnered with Eli Lilly to deploy a unique AI model, promising to compress drug development timelines from months to weeks. With a $1.3B valuation and investor backing from the likes of OpenAI and Thrive Capital, Chai's collaboration with Eli Lilly stands as a testament to AI's disruptive power in pharmaceuticals.
Jan 17